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Abstract
Purpose To examine differences in effects according to growth hormone (GH) treatment duration in adult GH-deficient 
patients.
Methods In the Italian cohort of the observational Hypopituitary Control and Complications Study, GH-treated adults with 
GH deficiency (GHD) were grouped by duration of treatment; ≤ 2 years (n = 451), > 2 to ≤ 6 years (n = 387) and > 6 years 
(n = 395). Between-group differences in demographics, medical history, physical characteristics, insulin-like growth factor-I 
standard deviation score (IGF-I SDS) and lipid profile at baseline, last study visit and changes from baseline to last study 
visit were assessed overall, for adult- and childhood-onset GHD and by gender using ANOVA for continuous variables and 
Chi-squared test for categorical variables.
Results At baseline, treatment duration groups did not differ significantly for age, gender, body mass index, GHD onset, 
IGF-I SDS, lipid profile, and quality of life. Mean initial GH dose did not differ significantly according to treatment duration 
group in any subgroup, except female patients, with highest mean dose seen in the longest duration group. In the longest 
duration group for patients overall, adult-onset patients and male patients, there were significant decreases in GH dose from 
baseline to last visit, and in total and low-density lipoprotein (LDL)-cholesterol concentrations. IGF-I SDS increased, to a 
greater extent, in the longest duration group for patients overall and female patients.
Conclusions The results show that long-term GH treatment is associated with decreasing GH dose, increased IGF-I, decreased 
LDL-cholesterol and the presence of surrogate markers that help to give confidence in a diagnosis of GHD.
Keywords Growth hormone deficiency · Growth hormone treatment · Adult · GH dose · Insulin-like growth factor-I · Lipid 
profile
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Introduction
Growth hormone (GH) deficiency in adult patients is asso-
ciated with increased risk of mortality, predominantly due 
to cardiovascular disease [1–4]. GH-deficient patients fre-
quently have excess body fat, decreased lean body mass 
and an abnormal lipid profile, and GH treatment is able 
to reverse these effects [2–8]. Adult patients diagnosed as 
having GH deficiency require continuous treatment with 
GH throughout their lives to maintain the metabolic bene-
fits. However, the effects of such continuous GH treatment 
may change over time and data are required to evaluate 
such potential changes.
Data from large observational studies indicate that 
duration of GH treatment varies widely from a few months 
to many years. However, only limited data have been pub-
lished that enable comparison of metabolic and hormonal 
effects between short-term versus long-term GH treat-
ment [8, 9]. In the observational Hypopituitary Control 
and Complications Study (HypoCCS) programme, data 
have been collected for a large number of adult patients 
with GH deficiency who were treated with GH [10, 11]. 
Among the 16 countries in Europe and North America that 
enrolled patients into HypoCCS, Italy was a major con-
tributing country to the database [12]. The present analysis 
used the Italian cohort of patients in HypoCCS, which 
included data from patients with various durations of GH 
treatment. The present analysis was carried out to examine 
differences in baseline characteristics, efficacy and quality 
of life between patients who received GH treatment for 
different durations, to investigate changes in effects during 
short-term versus long-term treatment.
Methods
Patients and study design
HypoCCS was a multi-national surveillance study 
designed to examine the safety and efficacy of long-
term GH treatment in adult patients with GH deficiency. 
Patients entered into the study were adults, aged at least 
18 years, with onset of GH deficiency either during child-
hood (CO) or adulthood (AO). Because HypoCCS was a 
surveillance study, the diagnosis of GH deficiency, entry 
into the study and all treatment decisions were at the dis-
cretion of the attending physician according to local guide-
lines. The Italian cohort of patients who entered into the 
present analysis met the criteria for the indication of adult 
treatment with GH, according to Italian reimbursement 
rules described in Nota AIFA no. 39.
Other than a diagnosis of GH deficiency, the only inclu-
sion criterion for entry to HypoCCS was that patients had 
achieved adult height, with closed epiphyses. Exclusion 
criteria included active malignancy, recent growth of a 
pituitary adenoma or other intracranial tumour, presence 
of acute critical illness due to complications following 
open heart or abdominal surgery, multiple accidental trau-
mas, or acute respiratory failure.
HypoCCS was registered with ClinicalTrials.gov, study 
number NCT01088399. The clinical study protocol was 
approved by appropriate institutional review boards and 
adhered to all applicable regulatory requirements. All 
patients provided signed informed consent for data collec-
tion, electronic processing and publication, in accordance 
with national laws. The study was performed according to 
the ethical principles of the Declaration of Helsinki.
Study evaluations
Data collected at baseline and during follow-up included 
demographics, medical history, height, weight, body mass 
index (BMI), insulin-like growth factor-I (IGF-I) con-
centrations, lipid profile and Framingham cardiovascular 
risk index. Study visits for clinical assessment occurred 
at approximately 6- to 12-month intervals, although time 
between visits was flexible, in line with clinical practice.
Peak GH concentration following stimulation testing 
was determined at local laboratories using commercially 
available GH assays. IGF-I concentration was measured at 
a central laboratory (IGF Labor, Universitats Kinderklinik, 
Giessen, Germany) and values were converted to standard 
deviation scores (SDS) based on age- and gender-matched 
reference ranges, using published methods [13]. Concen-
trations of total cholesterol, low-density lipoprotein (LDL)-
cholesterol, high-density lipoprotein (HDL)-cholesterol and 
triglycerides were assessed locally using the routine proce-
dures of the hospital laboratories. The Framingham cardio-
vascular index was determined as 10-year risk according to 
published calculations [14]. The risk score was calculated 
as the sum of by-gender sub-scores of age, total cholesterol 
level, HDL-cholesterol level, smoking history and systolic 
blood pressure determined at each time point. Quality of 
life was evaluated from the Questions on Life Satisfaction-
Hypopituitarism (QLS-H) questionnaire and Z-scores cal-
culated from normative data [15].
Data analysis and statistics
Data were analysed for patients in Italy who were fol-
lowed in HypoCCS from 1995 to December 2012. Dura-
tion of GH treatment for these patients ranged from < 1 
to > 16 years. For the present analysis, the patients were 
divided into three groups based on duration of therapy: 
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group A received GH treatment for ≤ 2 years (n = 451), 
group B received GH for > 2 to ≤ 6 years (n = 387) and 
group C received GH for > 6 years (n = 395). The fol-
lowing parameters were evaluated: demographics, GH 
deficiency diagnosis, BMI, lipid profile, GH dose, IGF-I 
SDS, Framingham cardiovascular risk and quality of life. 
Data are shown as mean ± standard deviation or with 95% 
confidence intervals (CI) for continuous variables, and 
number of patients (percentage of total patient number) 
for categorical variables. Baseline variables and changes 
from baseline to last available visit on GH treatment were 
compared across treatment duration groups. Differences 
between the duration of treatment groups were assessed 
using ANOVA for continuous variables and Chi-squared 
tests for categorical variables, with P < 0.05 consid-
ered statistically significant. All analyses of differences 
between duration groups were repeated for subgroups 
based on the onset of GH deficiency (AO and CO), and 
gender (male and female). The effect of age at last visit 
was assessed for continuous variables using logistic 
regression with group C as the reference group, assessing 
effect of age and its interaction with treatment duration 
groups. No adjustments for multiplicity were made due 
to the ad hoc nature of the analysis.
Results
There were no statistically significant differences between 
the duration-of-treatment groups for mean baseline age, pro-
portion of males, BMI, onset of GH deficiency, lipid profile, 
IGF-I SDS or quality of life (Table 1). These parameters 
did not differ significantly when the groups were com-
pared within individual subgroups of AO, CO, male and 
female patients. Peak GH following GH-releasing hormone 
(GHRH) + arginine tests did not differ significantly between 
duration groups overall or for any individual subgroup.
There was a significant difference between the groups in 
the type of stimulation test used for diagnosis of GH defi-
ciency (Table 2). In group C, with the longest duration of 
GH treatment, the GHRH + arginine test was used more fre-
quently, and tests using either GHRH or arginine alone and 
the insulin tolerance test were used less frequently than for 
the other groups. The difference was significant overall and in 
AO, but not CO, patients and in male, but not female, patients.
The difference between groups for the cause of GH 
deficiency, as reported by the investigator, was statisti-
cally significant for AO patients, although not for patients 
overall or for CO patients (Table 3); there was also no sig-
nificant difference when analysed by gender. For the AO 
patients, there was a higher proportion with a diagnosis of 
craniopharyngioma and a lower proportion with idiopathic 
GH deficiency in group C with the longest treatment dura-
tion in the study.
Table 1  Patient demographics 
and characteristics at baseline
Data show mean ± SD or number of patients (% of total)
GH growth hormone, GHRH GH releasing hormone, LDL low-density lipoprotein, HDL high-density lipo-
protein, IGF-I insulin-like growth factor-I, SDS standard deviation scores
a GHRH + arginine test only, group A n  = 274, group B n = 262, group C n = 290
b Group A n = 95, group B n  = 121, group C n = 90
Group A (N = 451) Group B (N = 387) Group C (N = 395) P value
Age at baseline (years) 44.1 ± 16.2 43.8 ± 16.3 43.2 ± 14.8 0.699
Gender, male n (%) 253 (56%) 235 (61%) 235 (60%) 0.365
Body mass index (kg/m2) 28.6 ± 7.3 28.0 ± 6.1 27.7 ± 5.6 0.133
GH deficiency onset 0.345
 Adult onset n (%) 336 (75%) 303 (78%) 308 (78%)
 Childhood onset n (%) 115 (25%) 84 (22%) 87 (22%)
Peak stimulated GH (µg/l)a 2.7 ± 4.8 2.5 ± 2.5 2.2 ± 2.3 0.223
Lipid concentrations
 Total cholesterol (mg/dl) 210.0 ± 52.9 208.5 ± 47.8 212.5 ± 42.0 0.561
 LDL-cholesterol (mg/dl) 131.7 ± 46.7 130.2 ± 39.3 131.4 ± 38.4 0.918
 HDL-cholesterol (mg/dl) 50.1 ± 15.4 49.9 ± 14.1 51.4 ± 17.3 0.453
 Triglycerides (mg/dl) 151.0 ± 98.0 150.8 ± 101.1 141.0 ± 82.6 0.346
Framingham risk index 8.09 ± 7.57 7.44 ± 7.36 7.42 ± 7.05 0.493
IGF-I concentration (µg/l) 117.1 ± 81.4 106.7 ± 76.9 112.6 ± 86.9 0.433
IGF-I SDS − 2.28 ± 2.34 − 2.27 ± 2.14 − 2.73 ± 2.73 0.484
Quality of life Z-scoreb − 1.20 ± 1.45 − 1.07 ± 1.46 − 1.16 ± 1.24 0.777
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There was no statistical difference between the groups for 
mean GH dose at start of treatment, except in female patients 
where mean dose increased with increasing treatment dura-
tion (Table 4). Mean GH dose at the last study visit also 
did not differ significantly between groups, again, except 
for female patients where those with longest duration had 
a higher mean dose than those with shortest duration. The 
mean change in dose from baseline to last visit was signifi-
cantly different for patients overall and in AO, but not CO, 
and in male, but not female, patients. The largest decrease in 
all subgroups was seen in the group with the longest duration 
of treatment. GH dose at last visit was significantly affected 
by age (P < 0.001), but the interaction was not significant 
(P = 0.063) indicating that the age effect was similar in each 
group.
The increase in mean BMI from baseline to last visit 
differed significantly by treatment duration, increasing 
more in patients with the longest duration of treatment 
(Table 5). BMI at last visit was not significantly affected 
by age at last visit, either as a direct effect (P = 0.093) 
or interaction (P = 0.953). The significant difference 
between the groups for increase in mean BMI was seen 
overall and in CO patients, but not AO patients or in the 
by-gender analysis. The increase in mean IGF-I SDS at 
last visit was greater in group C with the longest dura-
tion of treatment. The difference between the groups for 
IGF-I SDS increase was significant overall and for female 
patients, but not for the other categories. Age at last visit 
had an effect on IGF-I SDS at last visit (P = 0.003), while 
the interaction with group effect was not significant 
(P = 0.300).
There was a decrease from baseline to last visit in mean 
total cholesterol and in mean LDL-cholesterol concentra-
tions in group C with the longest duration of treatment; 
for both concentrations, 95% CI excluded 0, indicating a 
significant effect, for patients overall and AO and male 
patients (Table 5). The interaction of age at last visit with 
treatment duration difference was significant for total 
cholesterol (P < 0.001) and LDL-cholesterol (P = 0.017) 
concentrations at last visit, indicating that the effect of 
age differed between the groups. Changes in triglyceride 
concentrations were very variable, with wide 95% CI, and 
showed little effect of GH treatment duration except for 
CO patients where the longest duration group showed 
an increase in concentration. There was a significant 
interaction of age with treatment duration on triglycer-
ide concentrations at last visit (P = 0.019). No significant 
between-group differences were seen for changes in HDL-
cholesterol concentration.
Table 2  GH stimulation tests used for GH deficiency diagnosis, by 
frequency of use
Data show number of patients (% of N)
GH growth hormone, GHRH GH-releasing hormone
Group A Group B Group C P value
All patients N = 424 N = 365 N = 378 0.008
 GHRH + arginine test 275 (65%) 263 (72%) 292 (77%)
 Insulin tolerance test 60 (14%) 47 (13%) 37 (10%)
 GHRH test 44 (10%) 19 (5%) 25 (7%)
 Arginine test 33 (8%) 19 (5%) 24 (6%)
Adult onset patients N = 323 N = 286 N = 293 0.031
 GHRH + arginine test 224 (69%) 218 (76%) 229 (78%)
 Insulin tolerance test 36 (11%) 30 (10%) 25 (9%)
 GHRH test 37 (12%) 19 (7%) 18 (6%)
 Arginine test 24 (7%) 10 (3%) 17 (6%)
Childhood onset patients N = 101 N = 79 N = 85 0.064
 GHRH + arginine test 51 (50%) 45 (57%) 63 (74%)
 Insulin tolerance test 24 (24%) 17 (22%) 12 (14%)
 GHRH test 7 (7%) 0 7 (8%)
 Arginine test 9 (9%) 9 (11%) 7 (8%)
Male patients N = 240 N = 220 N = 223 < 0.001
 GHRH + arginine test 151 (63%) 150 (68%) 185 (83%)
 Insulin tolerance test 40 (17%) 29 (13%) 18 (8%)
 GHRH test 28 (12%) 13 (6%) 8 (4%)
 Arginine test 18 (8%) 14 (6%) 13 (6%)
Female patients N = 184 N = 145 N = 155 0.106
 GHRH + arginine test 124 (67%) 113 (78%) 107 (69%)
 Insulin tolerance test 20 (11%) 18 (12%) 19 (12%)
 GHRH test 16 (9%) 6 (4%) 13 (6%)
 Arginine test 15 (8%) 5 (3%) 11 (7%)
Table 3  Reported cause of growth hormone deficiency
Group A Group B Group C P value
All patients N = 451 N = 387 N = 395 0.193
 Pituitary adenoma 181 (40%) 144 (37%) 170 (43%)
 Craniopharyngioma 51 (11%) 55 (14%) 60 (15%)
 Idiopathic 62 (14%) 48 (12%) 42 (11%)
 Other tumours 23 (5%) 28 (7%) 21 (5%)
 Other causes 134 (30%) 112 (29%) 102 (26%)
Adult onset patients N = 336 N = 303 N = 308 0.028
 Pituitary adenoma 177 (53%) 143 (47%) 164 (53%)
 Craniopharyngioma 36 (11%) 36 (12%) 43 (14%)
 Idiopathic 19 (6%) 26 (9%) 10 (3%)
 Other tumours 13 (4%) 24 (8%) 14 (5%)
 Other causes 91 (27%) 74 (24%) 77 (25%)
Childhood onset patients N = 115 N = 84 N = 87 0.055
 Pituitary adenoma 4 (3%) 1 (1%) 6 (7%)
 Craniopharyngioma 15 (13%) 19 (23%) 17 (20%)
 Idiopathic 43 (37%) 22 (26%) 32 (37%)
 Other tumours 10 (9%) 4 (5%) 7 (8%)
 Other causes 43 (37%) 38 (45%) 25 (29%)
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The mean Framingham cardiovascular risk index increased 
to a greater extent in the groups with longer duration of GH 
treatment, with no overlap of 95% CI values for group A 
(shortest duration) and group C (longest duration), for patients 
overall and AO and male patients. At last study visit (Table 5), 
there was a significant effect of treatment duration for patients 
overall and by category of AO and CO GH deficiency and in 
male patients, though not in female patients. There was no sig-
nificant effect of age at last visit on change in Framingham car-
diovascular risk at last visit (P = 0.593) and interaction of age 
with GH treatment duration was not significant (P = 0.064).
The QLS-H questionnaire was completed by only a limited 
number of patients. At baseline, the mean and 95% CI for the 
quality of life Z-score was below 0 for each group [group A 
− 1.20 (95% CI − 1.49 to − 0.90); group B −1.07 (95% CI 
− 1.33 to − 0.81); group C − 1.16 (95% CI − 1.42 to − 0.90)], 
with no significant difference between the treatment dura-
tion groups (P = 0.777). There were insufficient numbers of 
patients with available data to evaluate changes from baseline.
Discussion
Patients with GH deficiency, whether starting during adult-
hood or with onset during childhood and continuing in adult-
hood, require GH treatment throughout life to correct meta-
bolic abnormalities. Our analysis of metabolic parameters 
in adult patients with GH deficiency in Italy showed effects 
of duration of GH treatment on IGF-I SDS, BMI, lipids and 
Framingham cardiovascular risk. The analysis also indicated 
differences in the GH stimulation tests used and the diag-
nosed cause of the GH deficiency.
In Italy, the GHRH + arginine test was used for approxi-
mately 70% of patients, in contrast to the global data from 
HypoCCS where the test was used in less than a quarter of 
the patients [11]. In Italy, a higher proportion of patients 
in the longest GH treatment duration group received the 
GHRH + arginine test, whereas a lower proportion of 
patients received other tests. This could indicate that phy-
sicians were more confident about long-term GH replace-
ment for patients diagnosed as GH-deficient using the more 
sensitive and accurate GHRH + arginine test [16]. This was 
particularly noticeable for AO patients and was consistent 
with the less-frequent diagnosis of idiopathic GH deficiency 
and more-frequent diagnosis of craniopharyngioma in the 
AO patients in the longest duration of treatment group. How-
ever, it may also relate to changes over time in GH stimula-
tion tests and diagnoses that were observed previously for 
patients entered into HypoCCS between 1996 and 2005 [11].
GH dose for patients overall was not significantly differ-
ent between treatment duration groups at the start of treat-
ment, but was decreased from baseline to last study visit 
to a greater extent in the group with the longest treatment 
duration. In the patients with the longest GH treatment dura-
tion, the 95% CI did not include zero, indicating a significant 
decrease in dose. Because the aim was to assess changes 
according to duration of GH treatment, the whole cohort 
including all three groups was not analysed; however, a 
Table 4  Growth hormone (GH) 
dose (µg/kg/day) at start of 
treatment, at last visit, and the 
change from start to last visit for 
all patients with GH deficiency, 
and for GH deficiency group by 
time of onset
Data show mean (95% CI)
Group A Group B Group C P value
All patients N = 239 N = 335 N = 373
 Treatment start 5.2 (4.6 to 5.7) 5.5 (5.1 to 6.0) 5.6 (5.3 to 6.0) 0.328
 Last visit 5.0 (4.4 to 5.5) 5.9 (5.2 to 6.5) 5.3 (4.9 to 5.8) 0.076
 Change to last visit − 0.1 (− 0.3 to 0.1) 0.2 (− 0.1 to 0.6) − 0.4 (− 0.7 to − 0.2) 0.004
Adult onset patients N = 173 N = 261 N = 289
 Treatment start 4.2 (3.8 to 4.7) 4.7 (4.3 to 5.1) 5.0 (4.6 to 5.4) 0.064
 Last visit 4.2 (3.7 to 4.7) 5.1 (4.3 to 5.8) 4.6 (4.2 to 5.1) 0.149
 Change to last visit − 0.1 (− 0.3 to 0.2) 0.3 (− 0.2 to 0.7) − 0.4 (− 0.7 to − 0.1) 0.017
Childhood onset patients N = 66 N = 74 N = 84
 Treatment start 7.5 (6.1 to 8.9) 8.5 (7.2 to 9.9) 7.9 (7.1 to 8.7) 0.500
 Last visit 7.1 (5.8 to 8.4) 8.7 (7.3 to 10.0) 7.7 (6.8 to 8.6) 0.180
 Change to last visit − 0.1 (− 0.3 to 0.1) 0.1 (− 0.4 to 0.5) − 0.4 (− 0.9 to 0.0) 0.226
Male patients N = 133 N = 205 N = 221
 Treatment start 5.0 (4.2 to 5.9) 5.0 (4.4 to 5.5) 4.9 (4.5 to 5.3) 0.902
 Last visit 4.7 (3.9 to 5.4) 5.2 (4.3 to 6.1) 4.4 (4.0 to 4.7) 0.181
 Change to last visit − 0.3 (− 0.5 to 0.0) 0.2 (− 0.4 to 0.7) − 0.6 (− 0.9 to − 0.3) 0.030
Female patients N = 106 N = 130 N = 152
 Treatment start 5.3 (4.6 to 6.0) 6.4 (5.7 to 7.2) 6.8 (6.1 to 7.5) 0.015
 Last visit 5.4 (4.6 to 6.2) 6.9 (6.0 to 7.7) 6.7 (5.9 to 7.6) 0.037
 Change to last visit 0.2 (− 0.2 to 0.5) 0.3 (0.0 to 0.5) − 0.2 (− 0.6 to 0.2) 0.113
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previous analysis of the patients, on the basis of severity of 
GH deficiency, indicated that the dose increased over the 
first 5 years and then fluctuated [12], suggesting that for 
the whole cohort the dose decrease in the longer duration 
group was balanced by an increase in the shorter duration 
group. Mean doses in female patients were higher than in 
male patients at treatment start and last visit, with no overlap 
in 95% CI for the two longer duration groups, and in female 
patients no significant difference was seen between groups 
for change to last visit. This was consistent with the need 
for a higher GH dose in female patients and indicated that 
endocrinologists in Italy involved in HypoCCS were aware 
of the pathophysiological issue that female patients tend to 
be more resistant to GH than male patients [17–20]. Mean 
doses in patients with CO GH deficiency were higher than 
in those with AO GH deficiency, consistent with the require-
ment of a higher dose in patients at a younger age to opti-
mise body proportions [21]. GH dose in overall patients with 
the longest duration of treatment significantly decreased 
from baseline to last visit, as indicated by 95% CI values 
that did not include 0. This reduction in dose could reflect a 
decreased requirement based on the physiological decrease 
Table 5  Changes from baseline to last visit for body mass index, IGF-I SDS, lipid concentrations and Framingham cardiovascular risk index
Data show mean (95% CI)
LDL low-density lipoprotein, IGF-I insulin-like growth factor-I, SDS standard deviation scores, CI confidence interval
Group A Group B Group C P value
Body mass index (kg/m2)
 All patients 0.1 (− 0.1 to 0.3) 0.4 (0.1 to 0.7) 0.6 (0.3 to 1.0) 0.013
 Adult onset patients 0.1 (− 0.2 to 0.2) 0.2 (0.0 to 0.5) 0.3 (0.0 to 0.7) 0.319
 Childhood onset patients 0.3 (− 0.1 to 0.7) 1.0 (0.3 to 1.6) 1.7 (1.0 to 2.4) 0.003
 Male patients 0.1 (− 0.1 to 0.3) 0.2 (− 0.1 to 0.5) 0.5 (0.2 to 0.9) 0.102
 Female patients 0.2 (− 0.1 to 0.4) 0.7 (0.3 to 1.2) 0.8 (0.2 to 1.4) 0.071
IGF-I SDS
 All patients 1.3 (0.8 to 1.8) 1.1 (0.6 to 1.7) 2.2 (1.4 to 2.9) 0.039
 Adult onset patients 1.5 (0.9 to 2.1) 1.1 (0.5 to 1.6) 1.8 (1.2 to 2.5) 0.173
 Childhood onset patients 0.7 (− 0.5 to 1.8) 1.7 (− 0.5 to 3.8) 4.0 (0.5 to 7.5) 0.063
 Male patients 1.7 (1.0 to 2.4) 0.9 (0.3 to 1.5) 1.9 (1.0 to 2.8) 0.108
 Female patients 0.7 (0.1 to 1.3) 1.4 (0.5 to 2.4) 2.7 (1.2 to 4.1) 0.039
Total cholesterol (mg/dl)
 All patients − 1.6 (− 4.8 to 1.5) − 1.1 (− 6.4 to 4.3) − 10.1 (− 15.0 to − 5.2) 0.008
 Adult onset patients − 1.1 (− 4.6 to 2.5) − 3.8 (− 9.9 to 2.4) − 12.8 (− 18.4 to − 7.1) 0.005
 Childhood onset patients − 3.4 (− 10.4 to 3.5) 10.0 (− 0.8 to 20.8) − 0.6 (− 10.3 to 9.2) 0.109
 Male patients − 2.7 (− 6.6 to 1.3) 0.8 (− 5.9 to 7.4) − 15.3 (− 21.8 to − 8.9) < 0.001
 Female patients − 0.3 (− 5.4 to 4.8) − 3.8 (− 12.9 to 5.2) − 1.9 (− 9.3 to 5.5) 0.790
LDL cholesterol concentration (mg/dl)
 All patients − 2.4 (− 6.0 to 1.2) − 0.5 (−5.9 to 4.9) − 10.3 (− 15.3 to − 5.4) 0.008
 Adult onset patients − 1.6 (− 5.2 to 2.1) − 2.8 (− 8.8 to 3.3) − 13.1 (− 18.6 to − 7.6) 0.003
 Childhood onset patients − 5.7 (− 16.4 to 5.1) 10.4 (− 1.6 to 22.4) 0.7 (− 10.0 to 11.3) 0.142
 Male patients − 3.3 (− 8.4 to 1.8) 1.7 (− 5.4 to 8.8) − 12.3 (− 18.9 to − 5.7) 0.007
 Female patients − 1.2 (− 6.4 to 3.9) − 3.8 (− 12.2 to 4.7) − 7.0 (− 14.2 to 0.2) 0.511
Triglycerides (mg/dl)
 All patients − 2.0 (− 9.2 to 5.2) − 8.5 (− 18.6 to 1.6) 6.7 (− 3.8 to 17.1) 0.078
 Adult onset patients − 5.5 (− 13.8 to 2.9) − 6.1 (− 16.7 to 4.4) − 0.0 (− 11.1 to 11.1) 0.650
 Childhood onset patients 9.2 (− 5.2 to 23.5) − 20.6 (− 51.2 to 10.0) 30.3 (4.2 to 56.4) 0.016
 Male patients − 7.3 (− 17.8 to 3.2) − 10.6 (− 26.2 to 4.9) 3.2 (− 11.7 to 18.2) 0.340
 Female patients 5.0 (− 4.5 to 14.4) − 5.3 (− 15.5 to 4.8) 12.1 (− 0.9 to 25.1) 0.088
Framingham cardiovascular risk index
 All patients − 0.24 (− 0.66 to 0.18) 1.27 (0.87 to 1.67) 1.42 (1.03 to 1.81) < 0.001
 Adult onset patients − 0.10 (− 0.52 to 0.33) 1.17 (0.76 to 1.58) 1.57 (1.16 to 1.99) < 0.001
 Childhood onset patients − 0.62 (− 1.70 to 0.46) 1.67 (0.51 to 2.83) 0.79 (− 0.25 to 1.82) 0.027
 Male patients − 0.66 (− 1.12 to − 0.21) 1.42 (0.91 to 1.94) 1.45 (1.00 to 1.90) < 0.001
 Female patients 0.37 (− 0.41 to 1.14) 1.04 (0.41 to 1.66) 1.36 (0.63 to 2.09) 0.206
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of IGF-I with age [22, 23]. A significant direct effect of age 
at last visit was observed for GH dose at last visit, suggesting 
that the decrease in dose could possibly be more evident in 
patients with longer term treatment.
IGF-I SDS was increased to a greater extent in patients 
with longer duration of GH treatment overall, although this 
was associated more with female and CO patients reflecting 
their higher GH doses. Decreasing IGF-I with ageing has 
been shown in some studies to be associated with increased 
atherosclerosis and cardiovascular disease events [24–26], 
and it was reported that this was related to components of 
the metabolic syndrome [26]. An increase in BMI in the 
patients with the longest duration of treatment was observed, 
with a significant difference between duration groups. This 
was seen for patients overall, but was particularly apparent 
in patients with CO GH deficiency. While BMI generally 
tends to increase with age in the general population [27–29], 
no significant effect of age at last visit or interaction with 
duration of treatment was found; however, adult GH-defi-
cient patients have a higher BMI at a younger age with no 
change with increasing age [29] and when treated with GH, 
an increased BMI was only seen after 7 years or more [9].
Significant decreases in total and LDL-cholesterol con-
centrations occurred in the group of patients with the longest 
duration of GH treatment; this may indicate persistent effects 
of GH treatment on these parameters. The 95% CI values 
for decreases in both total cholesterol and LDL-cholesterol 
excluded 0 in the group with the longest duration of GH 
treatment for patients overall, AO patients and male patients. 
GH treatment of adult patients has been shown in several 
studies to decrease total and LDL-cholesterol levels [1, 4, 
8, 21]. In contrast to total and LDL-cholesterol, triglyceride 
concentrations appeared to increase in patients with longest 
duration of GH treatment; however, this was primarily due 
to an increase in the patients with CO GH deficiency. The 
results for triglycerides were in accordance with studies that 
generally show no effect of GH treatment on triglyceride 
concentrations [8, 10] and may simply reflect an increase 
with ageing.
Despite the decreased total and LDL-cholesterol con-
centrations in the group of patients with longest dura-
tion of GH therapy, the Framingham cardiovascular risk 
index increased in these patients as expected due to the 
progressive ageing of patients. The significant difference 
between GH treatment duration groups was seen overall, 
in patients with AO GH deficiency and in male patients. 
However, the increase in the Framingham cardiovascu-
lar risk index may be the result of the increased age of 
patients in the longest duration group. Total cholesterol 
was significantly decreased and HDL-cholesterol was not 
significantly changed, while LDL-cholesterol was signifi-
cantly increased but not included in Framingham score 
calculation. Additionally, systolic blood pressure was not 
analysed but considered unlikely to change, and the pro-
portion of smokers was similar during the study. There-
fore, it is clear that patients’ age at last visit is likely to 
have had a major impact on Framingham cardiovascular 
risk without having a significant effect overall. This would 
suggest that GH, at the dose used, could not control all 
the factors involved in cardiovascular risk and highlights 
the importance of continued observation of all factors 
associated with cardiovascular risk during long-term GH 
replacement in adult patients.
The strength of this study lies in providing data on GH 
therapy according to duration of follow-up that has been 
obtained from daily clinical practice.
In conclusion, in a real-life setting such as the Italian 
HypoCCS study, increased IGF-I SDS, decreased LDL-cho-
lesterol, more robust diagnostic tests and more severe causes 
of hypopituitarism (i.e. craniopharyngioma) are associated 
with a longer term duration of GH therapy. Thus, the pres-
ence of such surrogate markers that help to give confidence 
in a diagnosis of GH deficiency predicts a longer duration 
of treatment.
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